BRAF and melanoma: It is known that 50–60% of melanomas harbor activating BRAF mutation[1,2] and hence respond to BRAF inhibitors (BRAFi), but the duration of response is often short, despite adding MEK inhibitor to circumvent BRAFi resistance.